title: Hemolytic adverse events with immune globulin products: product factors and patient risks.
authors.affiliation: Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Dorothy E
authors.initials: DE
authors.lastname: Scott
authors.affiliation: Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Jay S
authors.initials: JS
authors.lastname: Epstein
mesh_terms: D000740:Anemia / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors